| 356 | 7 | 96 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 观察六君子汤合紫菀散配方颗粒治疗慢性阻塞性肺疾病（COPD）稳定期（肺脾气虚证）的临床疗效及对患者运动耐力的影响。方法 将77例慢性阻塞性肺疾病（COPD）稳定期（肺脾气虚证）患者随机分为观察组38例与对照组39例，对照组给予常规药物治疗，观察组在对照组的治疗基础上加服六君子汤合紫菀散配方颗粒，疗程均为8周。观察两组治疗前后临床疗效、主要中医症候积分、第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、第1秒用力呼气容积占用力肺活量百分比（FEV1/FVC%）、6min步行试验（6MWT）及安全性指标情况。结果 治疗后，观察组临床总有效率高于对照组（P<0.05）；两组患者咳嗽、咳痰、气短、乏力中医症候积分均降低（P<0.01），观察组的各项中医证候积分均低于对照组（P<0.05或P<0.01）；两组FEV1、FVC、FEV1/FVC%、6MWT均升高（P<0.05或P<0.01），且观察组上述指标均高于对照组（P<0.05）；两组安全指标无明显异常。结论 六君子汤合紫菀散配方颗粒可改善COPD稳定期的中医证候、肺功能和运动耐力，使用安全。
Abstract：[1] Hanson C,Bowser EK,Frankenfield DC,et al. Chronic Obstructive Pulmonary Disease:A 2019 Evidence Analysis Center Evidence-Based Practice Guideline[J]. J Acad Nutr Diet,2021,121(1):139-165.
[2] Lu HH,Zeng HH,Chen Y. Early chronic obstructive pulmonary disease:A new perspective[J]. Chronic Dis Transl Med,2021,7(2):79-87.
[3] Martinez FJ,Rabe KF,Ferguson GT,et al. Reduced AllCause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized,Double-Blind,Multicenter,ParallelGroup Study[J]. Am J Respir Crit Care Med,2021,203(5):553-564.
[4] Melhem O,Savage E,Lehane E. Symptom burden in patients with chronic obstructive pulmonary disease[J]. Appl Nurs Res,2021,57:151389.
[5] Hurst JR,Winders T,Worth H,et al. A Patient Charter for Chronic Obstructive Pulmonary Disease[J]. Adv Ther,2021,38(1):11-23.
[6] Li RT,Rao ZZ,Fu YH,et al. Prediction on the burden of disease of chronic obstructive pulmonary disease and simulation of the effectiveness of controlling risk factors in China by2030[J]. Zhonghua Liu Xing Bing Xue Za Zhi,2022,43(2):201-206.
[7] Hogea SP,Tudorache E,Fildan AP,et al. Risk factors of chronic obstructive pulmonary disease exacerbations[J]. Clin Respir J,2020,14(3):183-197.
[8] Rao Y,Le Y,Xiong J,et al. NK Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease[J]. Front Immunol,2021,12:666045.
[9] Li LC,Han YY,Zhang ZH,et al. Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management[J]. Drug Des Devel Ther,2021,15:111-124.
[10] Ren H,Jiang Y,Wang S,et al. Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease:A protocol for systematic review and meta-analysis[J]. Medicine(Baltimore),2021,100(1):e24198.
[11] Zhang CY,Li XX,Li P,et al. Consistency evaluation between dispensing granule and traditional decoction from Coptidis Rhizoma by using an integrated quality-based strategy[J]. Phytochem Anal,2021,32(2):153-164.
[12]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013(4):255-264.
[13]世界中医药学会联合会.国际中医临床实践指南慢性阻塞性肺疾病[J].世界中医药，2020,15(7):1084-1092.
[14]中华人民共和国卫生部.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002:30,54-58.
[15] Fan Y,Wen X,Zhang Q,et al. Effect of Traditional Chinese Medicine Bufei Granule on Stable Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-Analysis Based on Existing Evidence[J]. Evid Based Complement Alternat Med,2020,2020:3439457.
[16] Li Y,Xiong C,Zeng Y,et al. Acupuncture treatment of lung-spleen Qi deficiency in stable chronic obstructive pulmonary disease:a randomized,open-label,controlled trial[J]. J Tradit Chin Med,2019,39(6):885-891.
[17]张高，杨柳柳，晏显妮，等.培土生金膏在慢性阻塞性肺疾病稳定期应用探析[J].江苏中医药，2021,53(6):72-74.
[18]张婷，孙贵香，肖丹，等.四君子汤治疗脾胃气虚证的研究进展[J].江西中医药大学学报，2020,32(1):114-118.
[19] Fan YL,Miao Q,Liao X,et al. Systematic review and Meta-analysis on efficacy and safety of Liujunzi Decoction combined with Western medicine for stable chronic obstructive pulmonary disease[J]. Zhongguo Zhong Yao Za Zhi,2020,45(22):5331-5343.
[20] Chu X,Liu X J,Qiu J M,et al. Inhibitory effects of codonopsis pilosula polysaccharides on the deterioration of impaired phagocytosis of alveolar macrophage induced by fine particulate matter in chronic obstructive pulmonary disease mice[J]. Zhonghua Yi Xue Za Zhi,2016,96(14):1134-1138.
[21] Chen X,May B,Di YM,et al. Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD:a systematic review of effect on BODE index and six minute walk test[J]. PLoS One,2014,9(3):e91830.
[22] Deng L,Zhang X,Dong Y,et al.Erchen decoction combined with Sanziyangqin decoction for chronic obstructive pulmonary disease:A protocol for systematic review and metaanalysis[J]. Medicine(Baltimore),2020,99(40):e22315.
[23] Chen Y,Wu H,Li Y,et al. Aster tataricus attenuates asthma efficiently by simultaneously inhibiting tracheal ring contraction and inflammation[J]. Biomed Pharmacother,2020,130:110616.
[24] Yang L,Jiang H,Wang S,et al. Discovering the Major Antitussive,Expectorant,and Anti-Inflammatory Bioactive Constituents in Tussilago Farfara L. Based on the SpectrumEffect Relationship Combined with Chemometrics[J]. Molecules,2020,25(3):620.
[25] Chen Y,Dong J,Liu J,et al. Network PharmacologyBased Investigation of Protective Mechanism of Aster tataricus on Lipopolysaccharide-Induced Acute Lung Injury[J].Int J Mol Sci,2019,20(3):543.
[26] Liu C,Wu H,Wang L,et al. Farfarae Flos:A review of botany,traditional uses,phytochemistry,pharmacology,and toxicology[J]. J Ethnopharmacol,2020,260:113038.
[27] Wang D,Du Q,Li H,et al. The Isosteroid Alkaloid Imperialine from Bulbs of Fritillaria cirrhosa Mitigates Pulmonary Functional and Structural Impairment and Suppresses Inflammatory Response in a COPD-Like Rat Model[J].Mediators Inflamm,2016,2016:4192483.
[28] Li R,Zhai HQ,Tian WL,et al.[Comparative analysis between origin of cooked traditional Chinese medicine powder and modern formula granules][J]. Zhongguo Zhong Yao Za Zhi,2016,41(5):965-969.
基本信息:
中图分类号:R259
引用信息:
[1]陈少旭,梁小银,甘长朋,等.六君子汤合紫菀散配方颗粒治疗慢性阻塞性肺疾病的疗效观察[J].湖北中医杂志,2022,44(05):10-14.
2022-05-10
2022-05-10